CATX - AMEX

Perspective Therapeutics, Inc.

CATX·AMEX

$3.60

-1.1%

HealthcareMedical - Devices

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$278.10M

EPS-1.4000

P/E Ratio-1.97

Earnings Date08/12/2026

266.97M

Assets

-22%

3Y+360.0%

5Y+1621.0%

10Y+2076.0%

59.94M

Total Liabilities

19%

3Y+1638.0%

5Y+2088.0%

10Y+3496.0%

207.03M

Total Equity

-29%

3Y+279.0%

5Y+1521.0%

10Y+1853.0%

Perspective Therapeutics, Inc. Funding & Solvency Profile

CATX · AMEX

Current Assets

Cash & Cash Equivalents30.63M

Net Receivables6.00K

Inventory0.00

Other Current Assets3.65M

Total Current Assets148 M

Non-Current Assets

Property, Plant & Equipment78.10M

Goodwill & Intangible Assets40.00M

Long-Term Investments0.00

Other Non-Current Assets486.00K

Total Non-Current Assets79 M

Total Assets

266.97M

Financial Health Analysis

Current Ratio

5.17x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.29x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

120 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

56% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Perspective Therapeutics, Inc. Balance Sheet

CATX • AMEX

Perspective Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Jun 2022	Jun 2021	Jun 2020	Jun 2019	Jun 2018	Jun 2017	Jun 2016	Jun 2015	Jun 2014	Jun 2013	Jun 2012	Jun 2011	Jun 2010	Jun 2009	Jun 2008	Jun 2007
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	30.6M	61.6M	9.2M	21M	60.4M	9.6M	2.4M	5.3M	2.6M	5.9M	10.1M	5.2M	7.7M	2.9M	2.7M	2.1M	1.7M	3M	4.8M	9.4M
Short-Term Investments	114.1M	165.3M	0.0	22.8M	0.0	0.0	0.0	0.0	825K	3M	2.2M	9.4M	10M	0.0	0.0	0.0	0.0	1.7M	3.7M	9.9M
Cash & Short-Term Investments	144.7M	226.9M	9.2M	43.8M	60.4M	9.6M	2.4M	5.3M	3.4M	9M	12.4M	14.6M	17.7M	2.9M	2.7M	2.1M	1.7M	4.7M	8.5M	19.3M
Net Receivables	6K	116K	1.2M	1.4M	1.6M	1.7M	2M	1.2M	1.2M	726K	605K	1.1M	966.1K	935.3K	875K	1.2M	900.3K	746.6K	1M	1.1M
Accounts Receivables	6K	116K	1.2M	1.4M	1.6M	0.0	0.0	0.0	0.0	0.0	604.9K	1M	913K	923.8K	865.1K	792.8K	896.3K	746.6K	1M	1.1M
Other Receivables	0.0	0.0	10K	0.0	0.0	1.7M	2M	1.2M	1.2M	726K	108.0	19.6K	53.1K	11.5K	9.9K	425.9K	4K	0.0	0.0	0.0
Inventory	0.0	0.0	0.0	1.4M	1.1M	665K	645K	530K	516K	323K	334.4K	404K	359.7K	405.6K	444.3K	749.8K	681.7K	789.2K	900K	880.8K
Prepaids	0.0	0.0	1.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Assets	3.6M	4.1M	5.3M	6.7M	535K	301K	426K	305K	335K	271K	26.7K	26.7K	26.7K	26.7K	26.7K	141.2K	260K	151.1K	37.7K	145.2K
Total Current Assets	148.4M	231.2M	16.8M	53.2M	63.6M	12.3M	5.5M	7.3M	5.5M	10.3M	13.6M	16.3M	19.2M	4.4M	4.1M	4.2M	3.5M	6.4M	10.7M	21.7M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	78.1M	59.5M	6.3M	2.1M	2.6M	2.7M	2.7M	1.6M	1.3M	1.1M	576.7K	574.8K	1M	1.7M	2.4M	3.2M	4M	4.9M	6M	3.7M
Goodwill	0.0	0.0	24.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	40M	50M	50.4M	86K	107K	130K	138K	162K	198K	230K	150.5K	198.5K	223.8K	215.2K	203.3K	203.2K	218.3K	746.6K	478.4K	262.1K
Goodwill & Intangible Assets	40M	50M	74.4M	86K	107K	130K	138K	162K	198K	230K	150.5K	198.5K	223.8K	215.2K	203.3K	203.2K	218.3K	11.9K	478.4K	262.1K
Long-Term Investments	0.0	0.0	133K	150K	0.0	0.0	181K	181K	0.0	0.0	3M	5.1M	5.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Assets	0.0	0.0	0.0	0.0	0.0	0.0	-181K	-181K	0.0	0.0	0.0	46.5K	40.3K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	486K	405K	182K	-2.3M	926K	373K	137K	155K	478K	694K	772K	751.1K	651K	712.2K	749.2K	254.8K	247.7K	480.8K	563.4K	418.1K
Total Non-Current Assets	118.6M	109.9M	81.1M	2.3M	3.6M	3.2M	3.2M	2.1M	2M	2M	4.5M	6.7M	7.3M	2.6M	3.4M	3.7M	4.4M	5.4M	7.1M	4.3M
Other Assets	0.0	0.0	0.0	2.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Assets	267M	341.1M	97.9M	58.1M	67.3M	15.5M	8.7M	9.4M	7.5M	12.3M	18.1M	23M	26.5M	7.1M	7.5M	7.9M	7.9M	11.7M	17.8M	26.1M
LIABILITIES
CURRENT LIABILITIES
Total Payables	0.0	10.3M	6.9M	1.5M	847K	494K	654K	683K	1.4M	630K	612K	498.3K	574.9K	432.6K	389.1K	372.3K	404.4K	417K	751.4K	1.9M
Accounts Payable	0.0	10.3M	6.9M	1.5M	847K	494K	654K	683K	1.4M	630K	612K	498.3K	574.9K	432.6K	389.1K	0.0	0.0	746.6K	751.4K	1.9M
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	372.3K	404.4K	0.0	0.0	0.0
Accrued Expenses	0.0	0.0	3.9M	0.0	479K	378K	481K	296K	269K	338K	371K	466.4K	458.3K	252.7K	171.9K	401.9K	370.6K	470.6K	344.6K	461K
Short Term Debt	623K	52K	49K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	49.4K	161.4K	90K	244.1K
Capital Lease Obligations (Current)	0.0	957K	46K	0.0	260K	245K	236K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	0.0	0.0	211K	352K	89K	155K	138K	72.2K	212.8K	236.3K	127.4K	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	26.6M	1.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.9K
Other Current Liabilities	1.5M	5.5M	4.7M	-406K	259K	218K	204K	142K	175K	138K	111K	127.5K	120.8K	107.6K	88K	0.0	186.5K	0.0	0.0	131.1K
Total Current Liabilities	28.7M	18.2M	15.7M	2.7M	1.8M	1.3M	1.6M	1.1M	1.8M	1.1M	1.1M	1.1M	1.2M	792.9K	649K	774.2K	1M	1M	1.2M	2.8M
NON-CURRENT LIABILITIES
Long Term Debt	1M	1.6M	1.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	130.6K	176K	344.9K	528.2K
Deferred Revenue (Non-Current)	0.0	26.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	1.7M	2.5M	4.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	28.6M	55K	0.0	0.0	624K	753K	632K	621K	590K	561K	607K	1.1M	1.4M	896.2K	1M	662.2K	605.4K	553.5K	506K	0.0
Total Non-Current Liabilities	31.3M	32.2M	7M	0.0	1M	1.4M	1.4M	621K	590K	561K	607.5K	1.1M	1.4M	896.2K	1M	662.2K	735.9K	729.5K	850.9K	553.8K
Other Liabilities	0.0	0.0	0.0	116K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations	0.0	2.4M	826K	0.0	652K	897K	1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	25.6K
Total Liabilities	59.9M	50.4M	22.7M	3.4M	2.9M	2.7M	3M	1.7M	2.4M	1.7M	1.7M	2.2M	2.6M	1.7M	1.7M	1.4M	1.7M	1.8M	2M	3.4M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	59.0	59.0	59.0	59.0	59.0	59.0	59.0	59.0	59.0	59.0
Common Stock	74K	70K	282K	142K	142K	87K	69K	67K	56K	55K	55K	55K	54.7K	34.6K	31K	26.4K	23K	22.9K	22.9K	22.8K
Additional Paid-In Capital	0.0	522.4M	227.6M	0.0	159.4M	102.2M	93.6M	92.1M	84.3M	83.2M	82.8M	82.5M	82M	57.4M	54M	51.2M	48.1M	47.8M	47.5M	45.8M
Retained Earnings	-334.8M	-231.7M	-152.4M	-105.9M	-95.2M	-89.5M	-87.9M	-84.5M	-79.3M	-72.6M	-66.4M	-61.7M	-58.1M	-52.1M	-48.2M	-44.7M	-41.9M	-37.9M	-31.7M	-23.2M
Accumulated Other Comprehensive Income/Loss	110K	-51K	0.0	0.0	0.0	0.0	0.0	0.0	-7.7M	-7.6M	-7.5M	-7.1M	-6.5M	-5.9M	-5.2M	-4.3M	-4.1M	-3.2M	-2M	-767.9K
Other Total Stockholders' Equity	541.7M	0.0	0.0	160.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Stockholders' Equity	207M	290.7M	75.2M	54.6M	64.4M	12.8M	5.7M	7.7M	5M	10.6M	16.4M	20.8M	24M	5.4M	5.8M	6.5M	6.2M	10M	15.8M	22.7M
Total Equity	207M	290.7M	75.2M	54.6M	64.4M	12.8M	5.7M	7.7M	5M	10.6M	16.4M	20.8M	24M	5.4M	5.8M	6.5M	6.2M	10M	15.8M	22.7M
SUMMARY
Total Liabilities & Equity	267M	341.1M	97.9M	58.1M	67.3M	15.5M	8.7M	9.4M	7.5M	12.3M	18.1M	23M	26.5M	7.1M	7.5M	7.9M	7.9M	11.7M	17.8M	26.1M
Total Investments	114.1M	165.3M	133K	22.9M	0.0	0.0	181K	181K	825K	3M	5.2M	14.5M	15.4M	0.0	0.0	0.0	0.0	1.7M	3.7M	9.9M
Total Debt	1.6M	4.1M	2.6M	0.0	652K	897K	1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	180K	337.5K	434.9K	797.9K
Net Debt	-29M	-57.5M	-6.7M	-21M	-59.7M	-8.7M	-1.4M	-5.3M	-2.6M	-5.9M	-10.1M	-5.2M	-7.7M	-2.9M	-2.7M	-2.1M	-1.5M	-2.7M	-4.4M	-8.6M
Shares Outstanding	74,322,233	74,322,233	74,322,233	74,322,233	74,322,233	74,322,233	74,322,233	74,322,233	74,322,233	74,322,233	74,322,233	74,322,233	74,322,233	74,322,233	74,322,233	74,322,233	74,322,233	74,322,233	74,322,233	74,322,233

SEC Filings

CATX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 01, 2026	June 01, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 27, 2026	May 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 22, 2026	May 21, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 11, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 11, 2026	May 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 04, 2026	May 04, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 20, 2026	April 18, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 16, 2026	April 15, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 01, 2026	April 01, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 16, 2026	December 31, 2025	2025	View Filing

Showing 1 to 10 of 475 filings

Related Guides

Blog Categories

Continue your CATX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.